• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

    1/19/23 7:48:19 AM ET
    $AA
    $AIM
    $BGRY
    $BVXV
    Aluminum
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AA alert in real time by email

    Gainers

    • Tricida, Inc. (NASDAQ:TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.
    • Huadi International Group Co., Ltd. (NASDAQ:HUDI) rose 26.7% to $7.16 in pre-market trading after gaining over 3% on Wednesday.
    • Starbox Group Holdings Ltd. (NASDAQ:STBX) shares rose 22.1% to $3.65 in pre-market trading after the company reported a rise in FY22 earnings.
    • AIM ImmunoTech Inc. (NYSE:AIM) shares rose 15.8% to $0.73 in pre-market trading after dropping 18% on Wednesday. AIM ImmunoTech recently entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.
    • Zymeworks Inc. (NASDAQ:ZYME) rose 12% to $11.20 in pre-market trading.
    • Berkshire Grey, Inc. (NASDAQ:BGRY) shares rose 11.3% to $0.97 in pre-market trading after dropping 14% on Wednesday.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) rose 11% to $0.7680 in pre-market trading after jumping 15% on Wednesday. TransCode Therapeutics recently announced it received written authorization from the FDA that it may proceed with its First-in-Human Phase 0 clinical trial.
    • BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) rose 9.1% to $3.02 in pre-market trading after dropping 10% on Wednesday. BiondVax recently announced additional results from preclinical study showing SARS-COV-2 presence of in hamsters treated with BiondVax's NanoAb was below detectable levels.
    • CureVac N.V. (NASDAQ:CVAC) rose 8.4% to $10.28 in pre-market trading. UBS upgraded CureVac from Neutral to Buy and announced an $18 price target.
    • Humanigen, Inc. (NASDAQ:HGEN) rose 6.5% to $0.1683 in pre-market trading after dropping around 5% on Wednesday.

    Losers

    • Ontrak, Inc. (NASDAQ:OTRK) fell 12.8% to $0.9762 in pre-market trading. Ontrak shares jumped 95% on Wednesday after the company announced new data showing a reduction in depression and anxiety symptoms for Ontrak Health's Wholehealth+ program members.
    • Sigilon Therapeutics, Inc. (NASDAQ:SGTX) shares fell 14.2% to $0.4712 in pre-market trading. Sigilon Therapeutics shares jumped 33% on Wednesday after Canaccord Genuity initiated coverage on the stock with a Buy rating and a $6 price target.
    • Olink Holding AB (NASDAQ:OLK) shares fell 11.3% to $21.34 in pre-market trading after the company announced pricing of public offering of 5,831,028 American Depositary Shares at a price of $20 per ADS.
    • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) fell 10% to $18.55 in pre-market trading after the company reported a $125 million proposed public offering of common stock.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) fell 9.5% to $5.70 in pre-market trading after gaining around 28% on Wednesday. TC BioPharm recently announced a strategic collaboration to advance gamma-delta T cells in oncology.
    • Magic Empire Global Limited (NASDAQ:MEGL) fell 9.2% to $2.75 in pre-market trading after jumping 44% on Wednesday.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares fell 8.2% to $2.36 in pre-market trading after dropping over 15% on Wednesday.
    • Veris Residential, Inc. (NYSE:VRE) fell 8.1% to $14.95 in pre-market after the company outlined path to unlocking shareholder value.
    • Vapotherm, Inc. (NYSE:VAPO) shares dropped 7.1% to $1.45 in pre-market trading after dropping 14% on Wednesday.
    • Alcoa Corporation (NYSE:AA) fell 6.5% to $49.96 in pre-market trading after the company reported quarterly results and issued weak guidance.

     

    Get the next $AA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AA
    $AIM
    $BGRY
    $BVXV

    CompanyDatePrice TargetRatingAnalyst
    Alcoa Corporation
    $AA
    4/9/2026$80.00Equal-Weight → Overweight
    Morgan Stanley
    Alcoa Corporation
    $AA
    3/13/2026$68.00Underweight → Neutral
    Analyst
    Alcoa Corporation
    $AA
    1/27/2026$64.00Overweight → Equal-Weight
    Morgan Stanley
    Alcoa Corporation
    $AA
    1/13/2026$71.00Overweight → Equal Weight
    Wells Fargo
    Alcoa Corporation
    $AA
    1/8/2026$50.00Neutral → Underweight
    Analyst
    Zymeworks Inc.
    $ZYME
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    Zymeworks Inc.
    $ZYME
    10/24/2025$15.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AA
    $AIM
    $BGRY
    $BVXV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

    ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian cancerMedian duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months in ovarian and endometrial cancer cohortsFavorable tolerability profile and broad therapeutic window support continued clinical development  VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a div

    4/21/26 5:30:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

    Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor models New programs include Ly6E, CLDN18.2, and PTK7-targeting ADCs, as well as novel payload and platform innovations New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherape

    4/17/26 3:00:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alcoa Corporation Reports First Quarter 2026 Results

    Alcoa Corporation (NYSE:AA, ASX: AAI)) (Alcoa or the Company) today reported results for the first quarter 2026 that reflect improved profitability from higher aluminum prices. Financial Results and Highlights M, except per share amounts 1Q26   4Q25   1Q25   Revenue $ 3,193   $ 3,449   $ 3,369   Net income attributable to Alcoa Corporation $ 425   $ 213   $ 548   Earnings per common share $ 1.60   $ 0.80   $ 2.07   Adjusted net income attributable to Alcoa Co

    4/16/26 4:10:00 PM ET
    $AA
    Aluminum
    Industrials

    $AA
    $AIM
    $BGRY
    $BVXV
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.

    SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

    4/20/26 4:56:24 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alcoa Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alcoa Corp (0001675149) (Filer)

    4/16/26 4:12:31 PM ET
    $AA
    Aluminum
    Industrials

    SEC Form 10-K filed by TransCode Therapeutics Inc.

    10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    4/15/26 4:17:42 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $AIM
    $BGRY
    $BVXV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:19 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AA
    $AIM
    $BGRY
    $BVXV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AA
    $AIM
    $BGRY
    $BVXV
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Kristin Stafford as Chief Financial Officer

    VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a

    4/1/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $AIM
    $BGRY
    $BVXV
    Financials

    Live finance-specific insights

    View All

    Alcoa Corporation Reports First Quarter 2026 Results

    Alcoa Corporation (NYSE:AA, ASX: AAI)) (Alcoa or the Company) today reported results for the first quarter 2026 that reflect improved profitability from higher aluminum prices. Financial Results and Highlights M, except per share amounts 1Q26   4Q25   1Q25   Revenue $ 3,193   $ 3,449   $ 3,369   Net income attributable to Alcoa Corporation $ 425   $ 213   $ 548   Earnings per common share $ 1.60   $ 0.80   $ 2.07   Adjusted net income attributable to Alcoa Co

    4/16/26 4:10:00 PM ET
    $AA
    Aluminum
    Industrials

    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr

    4/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alcoa Schedules First Quarter 2026 Earnings Release and Conference Call

    Alcoa Corporation (NYSE:AA, ASX: AAI)) plans to announce its first quarter 2026 financial results on Thursday, April 16, 2026, after the close of trading on the New York Stock Exchange. Alcoa will host a conference call to discuss the first quarter 2026 financial results on April 16, 2026, at 5:00 p.m. EDT (April 17, 2026, at 7:00 a.m. AEST). The call will be webcast live via Alcoa's website, www.alcoa.com. The first quarter 2026 earnings press release with financial results, and a related presentation, will be available on the "Investors" section of Alcoa's website, www.alcoa.com. A link to the press release will also be on Alcoa's X handle @Alcoa at www.X.com/Alcoa. Conference Call

    3/16/26 8:30:00 AM ET
    $AA
    Aluminum
    Industrials

    $AA
    $AIM
    $BGRY
    $BVXV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Olson Emily M.

    4 - Alcoa Corp (0001675149) (Issuer)

    4/17/26 4:30:18 PM ET
    $AA
    Aluminum
    Industrials

    SEC Form 3 filed by new insider Olson Emily M.

    3 - Alcoa Corp (0001675149) (Issuer)

    4/15/26 4:31:23 PM ET
    $AA
    Aluminum
    Industrials

    SEC Form 3 filed by new insider Xiang Jianping

    3 - Huadi International Group Co., Ltd. (0001791725) (Issuer)

    4/10/26 4:25:21 PM ET
    $HUDI
    Steel/Iron Ore
    Industrials

    $AA
    $AIM
    $BGRY
    $BVXV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcoa upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Alcoa from Equal-Weight to Overweight and set a new price target of $80.00

    4/9/26 8:21:40 AM ET
    $AA
    Aluminum
    Industrials

    Alcoa upgraded by Analyst with a new price target

    Analyst upgraded Alcoa from Underweight to Neutral and set a new price target of $68.00

    3/13/26 8:39:24 AM ET
    $AA
    Aluminum
    Industrials

    Alcoa downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Alcoa from Overweight to Equal-Weight and set a new price target of $64.00

    1/27/26 8:39:42 AM ET
    $AA
    Aluminum
    Industrials